Associate Dean of Medical Education Professor of Molecular Pharmacology/Clinical Biochemistry/Medicinal Chemistry/Biomedical Sciences, College of Medicine
Office: (916) 686 - 7438 Catherine.Yang@cnsu.edu
Dr. Yang has served as Associate Dean of Medical Education at the College of Medicine of California Northstate University (CNU) since 2018, overseeing the College's academic affairs and medical education operations. She also served as Interim Dean of the College from 2021 to 2023. She is a Professor of Molecular Pharmacology and Clinical Biochemistry in the Department of Basic Sciences at CNU's College of Medicine.
At CNU, Dr. Yang has played a leading role in developing and implementing the College's innovative, integrated, system-based medical education curriculum. Situated in Northern California, a region characterized by a highly diverse population, the program provides medical students with opportunities to develop the knowledge and clinical competencies necessary to address a broad spectrum of diseases and healthcare needs. She co-authored a medical education article describing the CNU College of Medicine's integrated, system-based curriculum and its underlying pedagogical approaches, published in the AAMC Academic Medicine journal in 2020.
Dr. Yang is also actively involved in special interest groups focused on artificial intelligence (AI) in the frontiers of medical research, as well as national AI initiatives, including the National Artificial Intelligence Research Resource (NAIRR). Her AI-assisted drug modeling research has led to the identification of a promising prostate cancer drug candidate. She also leads the Institute of Artificial Intelligence in Medical Sciences (IAiMedS).
With more than 25 years of teaching experience at five universities across the United States, Dr. Yang has taught a broad range of subjects, including Medicinal Chemistry, Molecular Pharmacology, Oncology, AI-Aided Drug Design, and Clinical Biochemistry. She has twice received the prestigious "Wall of Fame" recognition, having been selected by students as the professor who had the greatest impact on their professional careers.
Dr. Yang has authored more than 100 peer-reviewed research publications, several books in biotechnology and clinical applications, and is the inventor of 10 patented inventions. Her research and academic programs have received numerous grants and awards from the National Institutes of Health (NIH), National Science Foundation (NSF), Research Corporation, and New Jersey Health Foundation, in addition to substantial support from corporations and other health foundations.
In professional service and academic leadership, Dr. Yang serves as a board member of the Senior Leaders of Medical Education, Dean’s Council, Woman Dean’s Council and participates in various review panels for federal, private, and health foundation funding agencies. She also serves as Chair of the Board of Directors of a nonprofit educational foundation recognized as a 501(c)(3) organization.
Dr. Yang's research focuses on the role of proteolytic regulation in the progression of various diseases, particularly cancer. Her drug discovery programs target several major diseases, including type 2 diabetes, prostate cancer, leukemia, and lung cancer. Her research has made significant contributions to elucidating the molecular mechanisms underlying tumor progression and advancing the development of novel therapeutic agents for cancer treatment.
She has led NIH-funded research teams investigating proteolytic regulatory mechanisms associated with advanced-stage prostate cancer, lung cancer, and leukemia. Her extensive research on metabolic regulation in type 2 diabetes has resulted in a patent for a dual-function diabetes drug candidate.
Dr. Yang's immunological research has also led to the development of an innovative allergy vaccine that is currently undergoing clinical evaluation at affiliated clinics. Her research explores a novel immunotherapeutic approach involving the induction of immunological tolerance to external or autologous allergens, together with the induction of immune sensitization to infectious or tumor-associated antigens. By incorporating targeted tissue delivery systems and particles engineered to facilitate uptake by specific cell populations, this platform offers potential applications in the treatment of advanced-stage cancers and other immune-related diseases.
In addition, Dr. Yang is engaged in clinical trial studies involving her innovative leukemia drug candidate. Her pioneering work in predictive biomarker research has also contributed to the development of nanosensor technologies for early cancer detection.
In addition to her extensive research accomplishments, Dr. Yang has developed a strong commitment to advancing medical education. Her current interests encompass innovative curriculum design, integrated system-based learning, medical education pedagogy, and the application of artificial intelligence in medical education and research.
Before joining California Northstate University in 2016, Dr. Yang contributed to the development of the Rowan University Cooper Medical School. Her responsibilities included curriculum model development and pedagogical design, the establishment of research programs, planning and design of research facilities, and the development of hospital affiliations.
Through her combined expertise in medical education, biomedical research, drug discovery, and artificial intelligence, Dr. Yang continues to advance interdisciplinary approaches to medical training, scientific innovation, and translational medicine.